自然免疫グループ 業績リスト (2009 年以前)
＜原著論文、総説＞
2009 年・Comparative Immunological Analysis of Innate Immunity Activation after Oral
Administration of Wheat Fermented Extract to Teleost Fish.
Kadowaki T, Yasui Y, Takahashi Y, Kohchi C, Soma G, Inagawa H. Anticancer Res.
2009 Nov;29(11):4871-7.
・Correlation between WT1 expression and cell proliferation in endometrial cancer.
Dohi S, Ohno S, Ohno Y, Soma G, Kyo S, Inoue M. Anticancer Res. 2009
Nov;29(11):4887-91.
・Intracellular localization of CD14 protein in intestinal macrophages.
Yoshioka N, Taniguchi Y, Yoshida A, Nakata K, Nishizawa T, Inagawa H, Kohchi C,
Soma G. Anticancer Res. 2009 Mar;29(3):865-9.
・Two types of tumor necrosis factor-alpha in bluefin tuna (Thunnus orientalis) genes:
Molecular cloning and expression profile in response to several immunologicalstimulants.
Kadowaki T, Harada H, Sawada Y, Kohchi C, Soma G, Takahashi Y, Inagawa H. Fish
Shellfish Immunol. 2009 Nov;27(5):585-94.
・「自然免疫活性化物質 IP-PA1 の抗アレルギー効果」.
稲川裕之、河内千恵、杣源一郎. Medical Science Digest (ニューサイエンス社), 2009, 35
巻, 6 月号(通巻 453 号), p37-39.
・ROS and innate immunity.
Kohchi C, Inagawa H, Nishizawa T, Soma G. Anticancer Res. 2009 Mar;29(3):817-21.
・Utility and safety of LPS-based fermented flour extract as a macrophage activator.
Taniguchi Y, Yoshioka N, Nishizawa T, Inagawa H, Kohchi C, Soma G. Anticancer Res.
2009 Mar;29(3):859-64.
・The role of toll-like receptor 2 in survival strategies of Mycobacterium tuberculosis inmacrophage phagosomes.

Yoshida A, Inagawa H, Kohchi C, Nishizawa T, Soma G. Anticancer Res. 2009
Mar;29(3):907-10.
・Mechanism for maintaining homeostasis in the immune system of the intestine.
Taniguchi Y, Yoshioka N, Nakata K, Nishizawa T, Inagawa H, Kohchi C, Soma G.
Anticancer Res. 2009 Nov;29(11):4855-60.
・Intestinal macrophages involved in the homeostasis of the intestine have the potential
for responding to LPS.
Yoshioka N, Taniguchi Y, Yoshida A, Nakata K, Nishizawa T, Inagawa H, Kohchi C, Soma
G. Anticancer Res. 2009 Nov;29(11):4861-5.
・Improvement of allergic dermatitis via regulation of the Th1/Th2 immune systembalance by macrophages activated with lipopolysaccharide derived from Pantoea

agglomerans (IP-PA1).
Yoshida A, Kohchi C, Inagawa H, Nishizawa T, Soma G. Anticancer Res. 2009
Nov;29(11):4867-70.
・「健康志向性食品素材としてのグラム陰性菌リポ多糖（LPS）の可能性」.
稲川裕之、河内千恵、西澤孝志、中本優子、吉田彩、中本尊、吉村寛志、谷口芳枝、吉岡典子、中田和江、三宅信一郎、高松智、杣源一郎. New Food Industry, 2009, vol. 51, No. 5:
p37-42.
・High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced
cancer.
Ohno S, Ohno Y, Suzuki N, Soma G, Inoue M. Anticancer Res. 2009 Mar;29(3):809-15.
2008 年
・Stimulation of phagocytic activity of alveolar macrophages toward artificial
microspheres by infection with mycobacteria.
Hirota K, Tomoda K, Inagawa H, Kohchi C, Soma G, Makino K, Terada H. Pharm Res.
2008 Jun;25(6):1420-30. doi: 10.1007/s11095-007-9525-8.
・「結核治療を目的とした経肺吸収製剤」.
稲川裕之、河内千恵、杣源一郎、松本真、山本修司、寺田弘、牧野公子. Drug Delivery
System, 2008, July, Vol. 23 No. 4: p474-480.

・Preventative and Therapeutic Potential of Lipopolysaccharide Derived from Edible
Gram-Negative Bacteria to Various Diseases.
Soma GI, Inagawa H, Nishizawa T, Yoshioka N, Taniguchi Y, Kohchi, C. Current Drug
Therapy, Volume 3, Number 1, January 2008, pp. 26-32(7).
2007 年・Treatments for the activating macrophages that reduces surgical stress andpostoperative mortalities from bacterial infections and tumor metastases.
Nakamoto T, Yoshimura H, Honda T, Nakata K, Taniguchi Y, Yoshida A, Uenobe M,
Yoshioka N, Yamaguchi T, Inagawa H, Kohchi C, Nishizawa T, Soma G. In Vivo. 2007
Mar-Apr;21(2):357-64.
・Development and potential use of a monoclonal antibody to the lipopolysaccharide of
Pantoea agglomerans (IP-PA1).
Taniguchi Y, Nishizawa T, Honda T, Yoshioka N, Inagawa H, Kohchi C, Soma G.
Anticancer Res. 2007 Nov-Dec;27(6A):3701-6.
・Phagocytic activity of alveolar macrophages toward polystyrene latex microspheres
and PLGA microspheres loaded with anti-tuberculosis agent.
Hasegawa T, Hirota K, Tomoda K, Ito F, Inagawa H, Kochi C, Soma G, Makino K,
Terada H. Colloids Surf B Biointerfaces. 2007 Nov 15;60(2):221-8.
・Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA
microspheres by alveolar macrophages.
Hirota K, Hasegawa T, Hinata H, Ito F, Inagawa H, Kochi C, Soma G, Makino K,
Terada H. J Control Release. 2007 May 14;119(1):69-76.
・Cyclooxygenase-2 expression correlates with apoptosis and angiogenesis inendometrial cancer tissue.
Ohno S, Ohno Y, Suzuki N, Soma G, Inoue M. Anticancer Res. 2007 NovDec;27(6A):3765-70.
・Cloning and characterization of a TNF-like protein of Plecoglossus altivelis (ayufish).
Uenobe M, Kohchi C, Yoshioka N, Yuasa A, Inagawa H, Morii K, Nishizawa T,

Takahashi Y, Soma G. Mol Immunol. 2007 Feb;44(6):1115-22.
・Bioactive compounds from liverworts: Inhibition of lipopolysaccharide-induced
inducible NOS mRNA in RAW 264.7 cells by herbertenoids and cuparenoids.
Harinantenaina L, Quang DN, Nishizawa T, Hashimoto T, Kohchi C, Soma G, Asakawa
Y. Phytomedicine. 2007 Aug;14(7-8):486-91.
・Development of a drug delivery system using a model that mimics chronic infectionof Mycobacterium bovis Calmette-Guerin in alveolar macrophages.
Yoshida A, Inagawa H, Kohchi C, Nishizawa T, Hori H, Soma G. Anticancer Res. 2007
Nov-Dec;27(6A):3707-11.
・Suppression of response to foreign substances by intestinal macrophages.
Nakata K, Inagawa H, Nishizawa T, Kohchi C, Soma G. Anticancer Res. 2007 NovDec;27(6A):3723-7.
・「機能性糖脂質のスキンケア分野での有用性と利用」.
吉田彩、河内千恵、杣源一郎. Fragrance Journal, 2007, 臨時増刊, No. 20, p135-141.
・「マクロファージネットワークに基づいた食経験を持つグラム陰性菌リポ多糖の機能性食品素材（IP-PA1）への新展開」.
稲川裕之、河内千恵、杣源一郎. 日本補完代替医療学会誌, 2007, 6 月, 第 4 巻, 2 号, p79-90.
2006 年
・Identification and characterization of lipopolysaccharide in acetic acid bacteria.
Taniguchi Y, Nishizawa T, Kouhchi C, Inagawa H, Yamaguchi T, Nagai S, Tamura A,
Soma G. Anticancer Res. 2006 Nov-Dec;26(6A):3997-4002.
・A soluble 17 kDa tumour necrosis factor (TNF) mutein, TNF-SAM2, with membranebound TNF-like biological characteristics.
Yoshida A, Kohchi C, Inagawa H, Nishizawa T, Hori H, Soma G. Anticancer Res. 2006
Nov-Dec;26(6A):4003-7.
・Selective delivery of rifampicin incorporated into poly(DL-lactic-co-glycolic) acidmicrospheres after phagocytotic uptake by alveolar macrophages, and the killing effectagainst intracellular Mycobacterium bovis Calmette-Guérin.

Yoshida A, Matumoto M, Hshizume H, Oba Y, Tomishige T, Inagawa H, Kohchi C, Hino
M, Ito F, Tomoda K, Nakajima T, Makino K, Terada H, Hori H, Soma G. Microbes
Infect. 2006 Aug;8(9-10):2484-91.
・Cloning and characterization of a LPS-regulatory gene having an LPS binding
domain in kuruma prawn Marsupenaeus japonicus.
Nagoshi H, Inagawa H, Morii K, Harada H, Kohchi C, Nishizawa T, Taniguchi Y,
Uenobe M, Honda T, Kondoh M, Takahashi Y, Soma G. Mol Immunol. 2006
May;43(13):2061-9.
・Inherent potential for production of tumor necrosis factor-alpha by human intestinal
macrophages.
Nakata K, Inagawa H, Nishizawa T, Honda T, Kohchi C, Tonomoto Y, Yoshimura H,
Nagasue N, Natori S, Terada H, Soma G. Int J Colorectal Dis. 2006 May;21(4):339-47.
・Specific messenger RNA expression for signal transduction molecules by
lipopolysaccharide in intestinal macrophages.
Nakata K, Inagawa H, Nishizawa T, Kohchi C, Soma GI. Clin Exp Immunol. 2006
Mar;143(3):484-93.
・Inhibition of nitric oxide production in RAW 264.7 cells by azaphilones fromxylariaceous fungi.
Quang DN, Harinantenaina L, Nishizawa T, Hashimoto T, Kohchi C, Soma G, Asakawa
Y. Biol Pharm Bull. 2006 Jan;29(1):34-7.
・Chemical constituents of malagasy liverworts, part V: prenyl bibenzyls and clerodane
diterpenoids with nitric oxide inhibitory activity from Radula appressa andThysananthus spathulistipus.
Harinantenaina L, Takahara Y, Nishizawa T, Kohchi C, Soma G, Asakawa Y. Chem
Pharm Bull (Tokyo). 2006 Jul;54(7):1046-9.
・Grifolin derivatives from Albatrellus caeruleoporus, new inhibitors of nitric oxide
production in RAW 264.7 cells.
Quang DN, Hashimoto T, Arakawa Y, Kohchi C, Nishizawa T, Soma G, Asakawa Y.
Bioorg Med Chem. 2006 Jan 1;14(1):164-8.

・Expression of Tn and sialyl-Tn antigens in endometrial cancer: its relationship withtumor-produced cyclooxygenase-2, tumor-infiltrated lymphocytes and patient prognosis.
Ohno S, Ohno Y, Nakada H, Suzuki N, Soma G, Inoue M. Anticancer Res. 2006 NovDec;26(6A):4047-53.
・Evaluation of intratumoral administration of tumor necrosis factor-alpha in patientswith malignant glioma.
Oshiro S, Tsugu H, Komatsu F, Ohnishi H, Ueno Y, Sakamoto S, Fukushima T, Soma
G. Anticancer Res. 2006 Nov-Dec;26(6A):4027-32.
・Unique molecular characteristics of the environmental responses of mucosal
macrophages.
Nakata K, Inagawa H, Nishizawa T, Kohchi C, Taniguchi Y, Yoshioka N, Soma G.
Anticancer Res. 2006 Nov-Dec;26(6A):4009-14.
・Applications of lipopolysaccharide derived from Pantoea agglomerans (IP-PA1) for
health care based on macrophage network theory.
Kohchi C, Inagawa H, Nishizawa T, Yamaguchi T, Nagai S, Soma G. J Biosci Bioeng.
2006 Dec;102(6):485-96.
・「小麦発酵抽出物の自然免疫調節作用」.
河内千恵、稲川裕之、西澤孝志、山口高俊、高松智、永井史郎、杣源一郎. New Food Industry,
2006, vol. 48, No. 9: p19-27.
2005 年
・Molecular cloning and expression analysis of a macrophage-colony stimulating factor
receptor-like gene from rainbow trout, Oncorhynchus mykiss.
Honda T, Nishizawa T, Uenobe M, Kohchi C, Kuroda A, Ototake M, Nakanishi T,
Yokomizo Y, Takahashi Y, Inagawa H, Soma G. Mol Immunol. 2005 Jan;42(1):1-8.
・ Role of tumor-associated macrophages (TAM) in advanced gastric carcinoma: theimpact on FasL-mediated counterattack.
Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, Tachibana M, Ohno Y, Suzuki N, Inoue
M, Soma G, Nagasue N. Anticancer Res. 2005 Jan-Feb;25(1B):463-70.
・Establishment of an in vitro model using NR8383 cells and Mycobacterium bovis

Calmette-Guerin that mimics a chronic infection of Mycobacterium tuberculosis.
Hino M, Oda M, Yoshida A, Nakata K, Kohchi C, Nishizawa T, Inagawa H, Hori H,
Makino K, Terada H, Soma G. In Vivo. 2005 Sep-Oct;19(5):821-30.
・Innate-immune therapy for lung carcinoma based on tissue-macrophage activation
with lipopolysaccharide.
Hino M, Kohchi C, Nishizawa T, Yoshida A, Nakata K, Inagawa H, Hori H, Makino K,
Terada H, Soma G. Anticancer Res. 2005 Nov-Dec;25(6A):3747-54.
・ Role of cyclooxygenase-2 in immunomodulation and prognosis of endometrial
carcinoma.
Ohno Y, Ohno S, Suzuki N, Kamei T, Inagawa H, Soma G, Inoue M. Int J Cancer. 2005
May 1;114(5):696-701.
・Bis(bibenzyls) from liverworts inhibit lipopolysaccharide-induced inducible NOS in
RAW 264.7 cells: a study of structure-activity relationships and molecular mechanism.
Harinantenaina L, Quang DN, Takeshi N, Hashimoto T, Kohchi C, Soma G, Asakawa Y.
J Nat Prod. 2005 Dec;68(12):1779-81.
・Multiple roles of cyclooxygenase-2 in endometrial cancer.
Ohno S, Ohno Y, Suzuki N, Inagawa H, Kohchi C, Soma G, Inoue M. Anticancer Res.
2005 Nov-Dec;25(6A):3679-87.
・ A novel technology to prevent infectious diseases in aquaculture by modulatingcytokines.
Inagawa H, Kondoh M, Kohchi C, Soma GI, Yuasa A, Takahashi Y. Innovations andTechnologies in Oceanography for Sustainable Development, 2005, p29-43.
2004 年・Profile of cytokines produced in tumor tissue after administration of cyclophosphamide
in a combination therapy with tumor necrosis factor.
Takiguchi K, Nakamoto T, Inagawa H, Kohchi C, Nishizawa T, Nagasue N, Soma G.
Anticancer Res. 2004 May-Jun;24(3a):1823-8.
・ Correlation of histological localization of tumor-associated macrophages withclinicopathological features in endometrial cancer.

Ohno S, Ohno Y, Suzuki N, Kamei T, Koike K, Inagawa H, Kohchi C, Soma G, Inoue M.
Anticancer Res. 2004 Sep-Oct;24(5C):3335-42.
・Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicinloaded PLGA microspheres: effects of molecular weight and composition of PLGA on
release of rifampicin.
Makino K, Nakajima T, Shikamura M, Ito F, Ando S, Kochi C, Inagawa H, Soma G,
Terada H. Colloids Surf B Biointerfaces. 2004 Jul 1;36(1):35-42.
・Utilization of macrophages in anticancer therapy: the macrophage network theory.
Kohchi C, Inagawa H, Hino M, Oda M, Nakata K, Yoshida A, Hori H, Terada H, Makino
K, Takiguchi K, Soma G. Anticancer Res. 2004 Sep-Oct;24(5C):3311-20.
・「生体の防御システムを活用した慢性難治性感染症に対する DDS」.
寺田弘、杣源一郎、牧野公子. 薬剤学, 2004, Vol. 64, No. 5, p273-278.
2003 年・ Recombinantmutant

human

tumor

necrosisfactor-alpha(TNF-SAM2)

immunotherapy with ranimustine chemotherapy and concurrent radiation therapy formalignant astrocytomas.
Fukushima T, Yamamoto M, Oshiro S, Tsugu H, Hirakawa K, Soma G. Anticancer Res.
2003 Nov-Dec;23(6a):4473-81.
・The degree of macrophage infiltration into the cancer cell nest is a significant predictorof survival in gastric cancer patients.
Fukushima T, Yamamoto M, Oshiro S, Tsugu H, Hirakawa K, Soma G. Anticancer Res.
2003 Nov-Dec;23(6a):4473-81.
・Prognostic significance of tumor necrosis factor receptor in colorectal adenocarcinoma.
Yoshimura H, Dhar DK, Nakamoto T, Kotoh T, Takano M, Soma G, Nagasue N.
Anticancer Res. 2003 Jan-Feb;23(1A):85-9.
・Tumor-associated macrophages: foe or accomplice of tumors?
Ohno S, Suzuki N, Ohno Y, Inagawa H, Soma G, Inoue M. Anticancer Res. 2003 NovDec;23(6a):4395-409.

・「マクロファージと健康維持」.
杣源一郎、稲川裕之、河内千恵. 健康創造研究会誌, 2003, Vol. 2, No. 2, p105-112.
・「自然免疫とマクロファージ」.
杣源一郎、稲川裕之、河内千恵. Ｎews Letter, 2003, 2：17-20.
2002 年・Antitumor effects of isolated hypoxic hepatic perfusion (IHHP) with high-dose TNF
against colonic liver metastases in a rat model.
Nakamoto T, Inagawa H, Nishizawa T, Honda T, Kanou J, Nagasue N, Soma G.
Anticancer Res. 2002 Jul-Aug;22(4):2455-9.
・Treatment of recurrent malignant supratentorial astrocytomas with carboplatin andetoposide combined with recombinant mutant human tumor necrosis factor-alpha.
Yamamoto M, Oshiro S, Tsugu H, Hirakawa K, Ikeda K, Soma G, Fukushima T.
Anticancer Res. 2002 Jul-Aug;22(4):2447-53.
・ Development and characterization of a monoclonal antibody with cross-reactivity
towards uracil and thymine, and its potential use in screening patients treated with 5fluorouracil for possible risks.
Honda T, Inagawa H, Fukushima M, Moriyama A, Soma G. Clin Chim Acta. 2002
Aug;322(1-2):59-66.
・Cloning and characterization of the homolog of mammalian lipopolysaccharide-binding
protein and bactericidal permeability-increasing protein in rainbow trout Oncorhynchus

mykiss.
Inagawa H, Honda T, Kohchi C, Nishizawa T, Yoshiura Y, Nakanishi T, Yokomizo Y, Soma
G. J Immunol. 2002 Jun 1;168(11):5638-44.
・ Differential expression of two tumor necrosis factor genes in rainbow trout,

Oncorhynchus mykiss.
Zou J, Wang T, Hirono I, Aoki T, Inagawa H, Honda T, Soma GI, Ototake M, Nakanishi
T, Ellis AE, Secombes CJ. Dev Comp Immunol. 2002 Mar;26(2):161-72.
・Superoxide and Nitric Oxide Production of Kuruma Shrimp (Marsupenaeus japonicus)
Hemocytes.

Itami, T., Ohno, Y., Suzuki, N., Doi, K., Kondo, M., Takahashi, Y., Maeda, M., Soma,G-I.,
Inagawa, H., and Yokomizo, Y. Fisheries Science, 2002, 68: 1119-1122.
・Nitric Oxide Production by Carp Head Kidney Leukocytes.
Itami, T., Suzuki, N., Kondo, M., Takahashi, Y., Maeda, M., Soma,G-I., Inagawa, H.,
Kasornchandra J. and Yokomizo, Y. ITE Letters on Batteries,New Technologies &Medicine,2002, 3(6): 65-67.
・Role of tumor-associated macrophage in malignant tumors: should the location of theinfiltrated macrophages be taken into account during evaluation?
Ohno S, Inagawa H, Soma G, Nagasue N. Anticancer Res. 2002 Nov-Dec;22(6C):4269-75.
・Perspectives for antitumor therapy based on the recognition mechanism by whichmacrophages identify undesirable foreign and native cells and molecules.
Takiguchi K, Inagawa H, Nishizawa T, Kohchi C, Soma G. Anticancer Res. 2002 NovDec;22(6C):4277-80.
・「自然免疫における肺胞マクロファージの組織特異的性格」.
杣源一郎、稲川裕之、河内千恵. 膜(MEMBRANE), 2002, 27(5): p108-117.
・「自然免疫とマクロファージ」.
河内千恵、杣源一郎、稲川裕之. 日本補完代替医療学会誌, 2000.
2001 年
・Expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1, and c-Myc
in human astrocytomas.
Hayashi S, Yamamoto M, Ueno Y, Ikeda K, Ohshima K, Soma G, Fukushima T. Neurol
Med Chir (Tokyo). 2001 Apr;41(4):187-95.
・ Cloning and characterisation of tandem-repeat type galectin in rainbow trout(Oncorhynchus mykiss).
Inagawa H, Kuroda A, Nishizawa T, Honda T, Ototake M, Yokomizo U, Nakanishi T,
Soma G. Fish Shellfish Immunol. 2001 Apr;11(3):217-31.
・ Tumor necrosis factor alpha (TNFalpha)-like factor produced by macrophages inrainbow trout, Oncorhynchus mykiss.

Qin QW, Ototake M, Noguchi K, Soma G, Yokomizo Y, Nakanishi T. Fish Shellfish
Immunol. 2001 Apr;11(3):245-56.
・Clinical significance of the expression of nuclear factor-kappa B, tumor necrosis factor
receptor type I (TNFR1), and c-myc in human malignant astrocytomas 1.
Hayashi, S., Yamamoto, M., Fukushima, T., Ikeda, K., Ohshima, K., Kimura, H. Soma,GI. and Tomonaga, M. Neurologia medico-chirurgica (Tokyo),2001, 41: 187-95.
・Shrimp Hemocytes can produce superoxide and nitric oxide.
T Itami, Y Ohno, N Suzuki, K Doi, M Kondo, Y Takahashi, M Maeda, GI Soma, H
Inagawa, T Honda, Y Yokomizo. ITE Letters on Batteries, New Technology & Medicine,Vol. 2, No. 5, 2001.
2000 年
・Relationship between microvessel quantification and inducibility of endogenous tumor
necrosis factor in colorectal adenocarcinoma.
Yoshimura H, Chikamoto A, Honda T, Tashiro K, Nakamoto T, Takano M, Takagi K,
Nagasue N, Soma G. Anticancer Res. 2000 Jan-Feb;20(1C):629-33.
・Pharmacokinetics of isolated hepatic perfusion with high dose tumor necrosis factor in
rat model.
Nakamoto T, Inagawa H, Takagi K, Tashiro K, Yoshimura H, Nishizawa T, Honda T,
Kanou J, Muto Y, Amm E, Soma G. Anticancer Res. 2000 Jan-Feb;20(1C):619-22.
・Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor
type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant
astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNFSAM2).
Yamamoto M, Fukushima T, Hayashi S, Ikeda K, Tsugu H, Kimura H, Soma G,
Tomonaga M. Anticancer Res. 2000 Jan-Feb;20(1C):611-8.
・Clinical significance of the expression of endothelial-monocyte activating polypeptide
II (EMAPII) in the treatment of glioblastoma with recombinant mutant human tumor
necrosis factor-alpha (TNF-SAM2).
Yamamoto M, Fukushima T, Ueno Y, Hayashi S, Kimura H, Soma G, Tomonaga M.
Anticancer Res. 2000 Nov-Dec;20(6A):4081-6.

・ Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in
isolated limb perfusion in rats.
de Wilt JH, Soma G, ten Hagen TL, Kanou J, Takagi K, Nooijen PT, Seynhaevel AL,
Eggermont AM. Anticancer Res. 2000 Sep- Oct;20(5B):3491-6.
・Reduction of hepatotoxicity of tumor necrosis factor in isolated hepatic perfusion byadministration of glucocorticoid as well as lipopolysaccharide.
Nakamoto T, Inagawa H, Takagi K, Tashiro K, Yoshimura H, Nishizawa T, Honda T,
Kanou J, Muto Y, Soma G. Anticancer Res. 2000 Jan-Feb;20(1C):623-8.
・Enhancement of disease resistance against penaeid acute viraemia and induction ofvirus-inactivating activity in haemolymph of kuruma shrimp, Penaeus japonicus, by oral
administration of Pantoea agglomerans lipopolysaccharide (LPS).
Takahashi Y, Kondo M, Itami T, Honda T, Inagawa H, Nishizawa T, Soma GI, Yokomizo
Y. Fish Shellfish Immunol. 2000 Aug;10(6):555-8.
・「低分子量型リポ多糖(Pantoea agglomerans)の皮内投与により誘導される抗腫瘍効果に寄与するサイトカインネットワークの動的解析」.
杣源一郎. 薬学研究の進歩, 2000, 3 月 10 日発行、ｐ7-22.
・A new method of antitumor therapy with a high dose of TNF perfusion for unresectable
liver tumors.
Nakamoto T, Inagawa H, Takagi K, Soma G. Anticancer Res. 2000 Nov-Dec;20(6A):408796.
・The treatment of feline fibrosarcoma with lipopolysaccharide and cyclophosphamide;a case report.
Miller, E. J., Hadden III, W. A. and Soma,G-I. The Journal of the American Veterinary
Medical Association (2000 on line publication, http://www.priory.com/vet/feline.htm)
1999 年・TNFα like factor produced by macrophages in rainbow trout.
Qin Q., Ototake M., Noguchi K., Soma,G-I., Yokomizo Y., and Nakanishi T.
Developmental Comparative Immunology, 1999, 23: 704-705.

1998 年・Preservation of metastatic ability of colorectal tumor cells stratified by inducibility ofendogenous tumor necrosis factor after orthotopic transplantation in nude mice.
Soma G, Inagawa H, Fukushima Y, Kanou J, Tomita K, Takano M, Goto S, Takagi K.
Anticancer Res. 1998 Sep-Oct;18(5A):3427-32.
・Endogenous TNF inducibility and prognosis of colorectal cancer.
Takagi K, Tomita K, Fukushima Y, Chikamoto A, Kanou J, Honda T, Yoshimura H,
Nozaki R, Tashiro K, Soma G. Anticancer Res. 1998 Nov-Dec;18(6A):4141-6.
・ Involvement of 26-kDa membrane-bound tumour necrosis factor precursor inbidirectional feedback regulation on 17-kDa tumour necrosis factor production after
stimulation by lipopolysaccharide.
Tanabe Y, Kohchi C, Kitahara-Tanabe N, Mizuno D, Soma G. Cytokine. 1998
Feb;10(2):82-92.
・Mechanisms by which chemotherapeutic agents augment the antitumor effects oftumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 intumor lesions.
Inagawa H, Nishizawa T, Honda T, Nakamoto T, Takagi K, Soma G. Anticancer Res.
1998 Sep-Oct;18(5D):3957-64.
・Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis
factor-alpha (TNF-SAM2).
Fukushima T, Yamamoto M, Ikeda K, Tsugu H, Kimura H, Soma G, Tomonaga M.
Anticancer Res. 1998 Sep-Oct;18(5D):3965-70.
・ A large number of tandem repeats in the polymorphic epithelial mucin gene isassociated with severe acne.
Ando I, Kukita A, Soma G, Hino H. J Dermatol. 1998 Mar;25(3):150-2.
・Clinical experience of EET therapy for 75 advanced cancer patients.
Kato M, Shinohara H, Goto S, Takagi K, Soma G. Anticancer Res. 1998 SepOct;18(5D):3941-9.
・A long-term survivor case of malignant mesothelioma treated by recombinant tumor

necrosis factor-SAM2 (TNF-alpha mutein) and 5-fluorouracil (5-FU): a new therapeutic
approach based on host-tumor relationship.
Takagi K, Fukushima Y, Kanou J, Honda T, Tomita K, Takano M, Soma G. Anticancer
Res. 1998 Nov-Dec;18(6B):4591-600.
1997 年・ Structural characterization of lipid A obtained from Pantoea agglomeranslipopolysaccharide.
Tsukioka D, Nishizawa T, Miyase T, Achiwa K, Suda T, Soma G, Mizuno D. FEMS
Microbiol Lett. 1997 Apr 15;149(2):239-44.
・Augmentation of antitumor effect of endogenously induced tumor necrosis factor by
cyclophosphamide.
Inagawa H, Ohshiro S, Nishizawa T, Goto S, Soma G, Mizuno D. Anticancer Res. 1997
Jan-Feb;17(1A):55-60.
・Anti-tumor effect of lipopolysaccharide by intradermal administration as a novel drugdelivery system.
Inagawa H, Nishizawa T, Noguchi K, Minamimura M, Takagi K, Goto S, Soma G, Mizuno
D. Anticancer Res. 1997 May-Jun;17(3C):2153-8.
・Antitumor mechanism of intradermal administration of lipopolysaccharide.
Inagawa H, Nishizawa T, Takagi K, Goto S, Soma G, Mizuno D. Anticancer Res. 1997
May-Jun;17(3C):1961-4.
・Bidirectional feedback regulation on 17 kD tumor necrosis factor (TNF) production by
26 kD membrane-bound TNF precursor.
Soma GI, Nishizawa T, Inagawa H, Tanabe Y, Noguchi K, Goto S, Takagi K, Mizuno D.
J Inflamm. 1995-1996;47(1-2):52-60.
1996 年・Intradermal administration of lipopolysaccharide in treatment of human cancer.
Goto S, Sakai S, Kera J, Suma Y, Soma GI, Takeuchi S. Cancer Immunol Immunother.
1996 May;42(4):255-61.
・Induction of tumor necrosis factor by a camptothecin derivative, irinotecan, in miceand human mononuclear cells.
Goto S, Okutomi T, Suma Y, Kera J, Soma G, Takeuchi S. Anticancer Res. 1996 SepOct;16(5A):2507-11.
・Selective lysis of early embryonic cells by the alternative pathway of complement--a
possible mechanism for programmed cell death in embryogenesis.
Kircheis R, Kircheis L, Oshima H, Kohchi C, Soma G, Mizuno D. In Vivo. 1996 JulAug;10(4):389-403.
・Induction of differentiation in embryonic stem cells by 26-kD membrane-bound tumor
necrosis factor (TNF) and 17-kD free TNF.
Kohchi C, Tanabe Y, Noguchi K, Mizuno D, Soma G. In Vivo. 1996 Jan-Feb;10(1):19-27.
・ Mechanistic analysis of high antitumor effect of intradermal administration of
lipopolysaccharide from Pantoea agglomerans.
Iwamoto I, Goto S, Kera J, Soma G, Takeuchi S, Nagata Y. Med Oncol. 1996
Jun;13(2):103-9.
1995 年
・Augmentation of specific tumor killing activity by tumor-infiltrating lymphocytes (TIL)
in the presence of TNF-SAM2.
Goto S, Suma Y, Noguchi K, Kera J, Sakai S, Soma GI, Takeuchi S. Cancer Biother. 1995
Spring;10(1):37-44.
・Formulation and antitumor efficacy of liposomal-caprylated-TNF-SAM2.
Akimaru K, Auzenne E, Akimaru Y, Leroux ME, Hayman AC, Utsumi T, Soma G,
Klostergaard J. Cytokines Mol Ther. 1995 Sep;1(3):197-210.
・Inducibility of endogenous tumor necrosis factor by tumor cells from colorectal tumor
patients at Dukes stage C as a novel prognostic factor following curative operation.
Fukushima Y, Tanizaki E, Takagi K, Takano M, Soma G. Dis Colon Rectum. 1995
Oct;38(10):1059-66.
・ Molecular cloning of a cDNA that encodes the precursor to several exogastrulainducing peptides, epidermal-growth-factor-related polypeptides of the sea urchin

Anthocidaris crassispina.

Yamasu K, Watanabe H, Kohchi C, Soma G, Mizuno D, Akasaka K, Shimada H,
Suyemitsu T, Ishihara K. Eur J Biochem. 1995 Mar 1;228(2):515-23.
・Early embryonic cells activate the alternative complement system.
Kircheis R, Kircheis L, Oshima H, Kohchi C, Soma G, Mizuno D. In Vivo. 1995 MarApr;9(2):85-98.
・Hemodynamic evaluation of recombinant human tumor necrosis factor (TNF)-alpha,
TNF-SAM2 and liposomal TNF-SAM2 in an anesthetized dog model.
Lodato RF, Feig B, Akimaru K, Soma G, Klostergaard J. J Immunother Emphasis Tumor
Immunol. 1995 Jan;17(1):19-29.
・Formulation and antitumor efficacy of liposomal-caprylated-TNF-SAM2.
Akimaru K, Auzenne E, Akimaru Y, Leroux ME, Hayman AC, Utsumi T, Soma G,
Klostergaard J. Cytokines Mol Ther. 1995 Sep;1(3):197-210.
・Development and characterization of liposomal tumor necrosis factor (TNF).
Klostergaard, J., Akimaru, K., Soma,G-I. and Lodato, R. F. Journal of Liposome Research,
1995, 5: 491-502.
・「モルヒネ及びコカイン依存症治療薬としての Immunomodulator. 特に LPS の効用について」.
奥富隆文、鈴木勉. 薬学雑誌, 1995, 115(1): 42-51.
・「新しく展開する癌のバイオテラピーの概念」.
杣源一郎. Biotherapy, 1995, Feb, 9(2): 131-139.
・「低分子 Lipopolysaccharide (LPSp)皮内投与の抗腫瘍効果およびその臨床応用」.
後藤重則. Biotherapy, 1995, Feb, 9(2): 169-175.
1994 年
・Enhanced production of tumour necrosis factor alpha (TNF-alpha) by its precursor on
the cell surface of primed THP-1 cells.
Tanabe Y, Kitahara-Tanabe N, Mizuno D, Soma GI. Cytokine. 1994 Jul;6(4):337-48.
・Constitutive expression of TNF-alpha and -beta genes in mouse embryo: roles ofcytokines as regulator and effector on development.
Kohchi C, Noguchi K, Tanabe Y, Mizuno D, Soma G. Int J Biochem. 1994 Jan;26(1):1119.
・ A case report of recurrent cervical cancer which responded to a combination of
biological therapies.
Goto S, Sakai S, Kera J, Suma Y, Soma GI, Takeuchi S. Eur J Gynaecol Oncol.
1994;15(3):235-40.
・Antitumor effect of exogenous/endogenous TNF (EET) therapy with cyclophosphamide
on C6 glioma in rat.
Ohshiro S, Inagawa H, Soma G, Fukushima T, Tomonaga M. Cancer Biother. 1994
Winter;9(4):359-67.
・Effects of a lipopolysaccharide from Pantoea agglomerans on the cocaine-induced place
preference.
Suzuki T, Funada M, Sugano Y, Misawa M, Okutomi T, Soma G, Mizuno D. Life Sci.
1994;54(6):PL75-80.
・ Antinociceptive effect of lipopolysaccharide from Pantoea agglomerans on
streptozotocin-induced diabetic mice.
Kamei J, Iwamoto Y, Suzuki T, Misawa M, Kasuya Y, Nagase H, Okutomi T, Soma G,
Mizuno D. Eur J Pharmacol. 1994 Jan 4;251(1):95-8.
・ Suppression of hyperalgesia in streptozotocin-induced diabetic mice by alipopolysaccharide from Pantoea agglomerans.
Kamei J, Iwamoto Y, Suzuki T, Misawa M, Kasuya Y, Okutomi T, Soma G, Mizuno D.
Biol Pharm Bull. 1994 May;17(5):632-4.
・Clinical application of novel tumor necrosis factor(rTNF-SAM2) in colorectal cancer ( Areport of 13 cases).
Gao, F., Chen, L., Tang, Z., Wang P. Z. Takagi, K. and Soma,G-I. Acta Academiae
Medicinae Guangxi, 1994, 11: 144-148.
1993 年・Gangliosides can activate human alternative complement pathway.

Oshima H, Soma G, Mizuno D. Int Immunol. 1993 Oct;5(10):1349-51.
・Fc gamma receptor-mediated biological activities of human leukemic cell lines andtheir modulation by transforming growth factor-beta 1 and interleukin 6.
Morikawa M, Harada N, Nunomura Y, Koike T, Hashimoto S, Soma G, Yoshida T.
Cytokine. 1993 May;5(3):255-63.
・Promotion of metastases by tumor necrosis factor in rats bearing Dunning R3327 MATLyLu prostatic cancer.
Iizumi T, Yazaki T, Umeda T, Soma GI. Urol Int. 1993;51(2):85-8.
・Clinical significance of TNF production by colorectal cancer cell.
Takagi, K., Fukushima, Y., Takano, M and Soma,G-I. Annals of Cancer Research andTherapy, 1993, 2: 127-128.
・Further Development of the Therapy with Lipopolysaccharides of a Small Molecular
Size on Various Intractable Diseases.
Gen-Ichiro Soma, Den-ichi Mizuno. Molecular and Cellular Biology and ClinicalRelevance, 1993, p203-220.
1992 年・ Expression of transcripts of complement components and their receptors during
differentiation of embryonal carcinoma cell lines.
Kohchi C, Oshima H, Mizuno D, Soma G. Biochem Biophys Res Commun. 1992 Dec
15;189(2):863-8.
・Activation of the systemic production of tumor necrosis factor after exposure to acutestress.
Yamasu K, Shimada Y, Sakaizumi M, Soma G, Mizuno D. Eur Cytokine Netw. 1992 JulAug;3(4):391-8.
・ Inhibition of morphine dependence by a lipopolysaccharide from Pantoea agglomerans.
Okutomi T, Nishizawa T, Inagawa H, Soma G, Minami M, Satoh M, Mizuno D. Eur
Cytokine Netw. 1992 Jul-Aug;3(4):417-20.
・Oral or percutaneous administration of lipopolisaccharide of small molecular size maycure various intractable diseases: a new version of Coley's toxin.
Mizuno D, Soma G. Mol Biother. 1992 Dec;4(4):166-9.
・「TNF の抗腫瘍効果増強に関する工夫」.
杣源一郎. KARKINOS, 1992, 5：1291-1298.
・Homeostasis as regulated by activated macrophage. IX. Enhancement effect of LPSw
(a lipopolysaccharide from wheat flour) on hen egg-laying and breaking strength of
eggshell.
Suzuki J, Nishizawa T, Inagawa H, Okutomi T, Morikawa A, Soma G, Mizuno D. Chem
Pharm Bull (Tokyo). 1992 May;40(5):1274-6.
・Homeostasis as regulated by activated macrophage. VIII. LPSw (a lipopolysaccharide
from wheat flour) can regulate bone resorption of chick embryo.
Kawashima K, Endo H, Nishizawa T, Inagawa H, Okutomi T, Morikawa A, Soma G,
Mizuno D. Chem Pharm Bull (Tokyo). 1992 May;40(5):1271-3.
・ Homeostasis as regulated by activated macrophage. VII. Suppression of serum
cholesterol level by LPSw (a lipopolysaccharide from wheat flour) in WHHL (Watanabe
heritable hyperlipidemic) rabbit.
Okutomi T, Nishizawa T, Inagawa H, Takano T, Morikawa A, Soma G, Mizuno D. Chem
Pharm Bull (Tokyo). 1992 May;40(5):1268-70.
・Homeostasis as regulated by activated macrophage. VI. Protective effect of LPSw (alipopolysaccharide from wheat flour) against acute infection by Toxoplasma gondii inmice.
Suzuki Y, Kobayashi A, Nishizawa T, Inagawa H, Morikawa A, Soma G, Mizuno D. Chem
Pharm Bull (Tokyo). 1992 May;40(5):1266-7.
・Homeostasis as regulated by activated macrophage. V. Suppression of diabetes mellitus
in non-obese diabetic mice by LPSw (a lipopolysaccharide from wheat flour).
Iguchi M, Inagawa H, Nishizawa T, Okutomi T, Morikawa A, Soma GI, Mizuno D. Chem
Pharm Bull (Tokyo). 1992 Apr;40(4):1004-6.
・Homeostasis as regulated by activated macrophage. IV. Analgesic effect of LPSw, alipopolysaccharide of wheat flour.

Okutomi T, Nishizawa T, Inagawa H, Morikawa A, Takeuchi S, Soma GI, Mizuno D.
Chem Pharm Bull (Tokyo). 1992 Apr;40(4):1001-3.
・Homeostasis as regulated by activated macrophage. III. Protective effect of LPSw
(lipopolysaccharide (LPS) of wheat flour) on gastric ulcer in mice as compared with thoseof other LPS from various sources.
Inagawa H, Saitoh F, Iguchi M, Nishizawa T, Okutomi T, Morikawa A, Soma GI, Mizuno
D. Chem Pharm Bull (Tokyo). 1992 Apr;40(4):998-1000.
・Homeostasis as regulated by activated macrophage. II. LPS of plant origin other thanwheat flour and their concomitant bacteria.
Inagawa H, Nishizawa T, Tsukioka D, Suda T, Chiba Y, Okutomi T, Morikawa A, Soma
GI, Mizuno D. Chem Pharm Bull (Tokyo). 1992 Apr;40(4):994-7.
・Homeostasis as regulated by activated macrophage. I. Lipopolysaccharide (LPS) from
wheat flour: isolation, purification and some biological activities.
Nishizawa T, Inagawa H, Oshima H, Okutomi T, Tsukioka D, Iguchi M, Soma G, Mizuno
D. Chem Pharm Bull (Tokyo). 1992 Feb;40(2):479-83.